HOME ·

01672.HK

ASCLETIS-B (01672.HK): ASC36_35FDC preclinical data presented at EASD 2026
Tags：
ASCLETIS-B01672.HKR&D Progress
2026-10-02
ASCLETIS-B (01672.HK): Initiates US Phase I Study of Oral Amylin Receptor Agonist Peptide ASC36 for Obesity; Up to 13.2% Weight Loss in Non-human Primates
Tags：
ASCLETIS-B01672.HKR&D Progress
2026-09-08
ASCLETIS-B (01672.HK): Included in Stock Connect list under Shanghai-Hong Kong and Shenzhen-Hong Kong schemes effective 7 September
Tags：
ASCLETIS-B01672.HKStock Connect
2026-09-07
ASCLETIS-B(01672.HK)2026 Interim Report - Profit Attributable to Shareholders stood at loss of CNY 319.67 million, loss widened by 263.46% YoY
Tags：
ASCLETIS-B01672.HKNewTimeSpace
2026-09-01
ASCLETIS-B (01672.HK): First subject dosed in global Phase III program of oral GLP-1 agonist ASC30 for long-term weight management, targeting ~4,600 subjects
Tags：
ASCLETIS-B01672.HKClinical Trial
2026-08-30
Ascletis-B (01672.HK): Oral Small-molecule GLP-1 ASC30 Initiates Global Phase III Clinical Trials; First-in-class Triple-target FDC Achieves 15.2% Weight Loss in Preclinical Studies
Tags：
ASCLETIS-B01672.HKClinical Trial
2026-08-03
ASCLETIS-B (01672.HK): ASC36_35 FDC Exhibits Superior Weight-Loss Efficacy versus Eloralintide Combined with Tirzepatide; Preclinical Data to Be Presented at EASD 2026
Tags：
ASCLETIS-B01672.HKpreclinical data
2026-07-23
Ascletis Pharma(01672.HK): Fixed-Dose Combination of GIPR Agonist ASC48 and GLP-1R Agonist ASC30 Selected for Clinical Development
Tags：
Ascletis Pharma01672.HK
2026-07-15
Ascletis Pharma(01672.HK): Proposed Share Repurchase of Up to HK$300 Million
Tags：
Ascletis Pharma01672.HK
2026-06-30